Form 4: Halozyme Therapeutics Director Connaughton Reports Stock and Option Awards

Director Bernadette Connaughton reports the acquisition of restricted stock units and stock options in Halozyme Therapeutics under the company's director compensation program.

Summary

• Bernadette Connaughton, a director of Halozyme Therapeutics, reported transactions involving the company's stock.
• On May 1, 2025, Connaughton acquired 4,165 shares of common stock through a restricted stock unit (RSU) grant and an option to purchase 5,750 shares.
• The RSU grant vests fully on the earlier of May 1, 2026, or the date of the next annual meeting of stockholders.
• The stock option grant also vests fully on the earlier of May 1, 2026, or the date of the next annual meeting of stockholders, with an exercise price of $60.03.
• Following the reported transactions, Connaughton beneficially owns 50,952 shares of common stock and options to purchase 5,750 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The document reflects standard director compensation practices, which are generally viewed favorably as they align director interests with shareholder value. There are no indications of negative events or concerns.

Positives

• The grants of RSUs and stock options to a director align her interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Industry Context

Director compensation packages often include stock options and RSUs to align the interests of directors with those of shareholders, incentivizing them to work towards increasing shareholder value. This is a standard practice in the biotechnology industry.

Comparison to Industry Standards

• Stock option and RSU grants are common components of director compensation packages in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation to incentivize their directors.
• The vesting schedules, typically one year, are also in line with industry norms.

Stakeholder Impact

• The grants align the director's interests with those of shareholders, potentially leading to decisions that increase shareholder value.
• The compensation structure may influence employee morale positively, as it reflects a commitment to rewarding leadership.

Key Dates

Keywords

Halozyme Therapeutics, Director Compensation, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, Connaughton, HALO